Cancer and Immunomodulators in Inflammatory Bowel Diseases
Authors:
- Sara OnaliSOSara Onali
- Carmelina PetruzzielloCPCarmelina Petruzziello
- Emma CalabreseECEmma Calabrese
- Francesco PalloneFPFrancesco Pallone
- 1 March 2015
- journal article
- review article
- Published by Oxford University Press (OUP) in Inflammatory Bowel Diseases
- Vol. 21 (3) , 674-698
Abstract
The widespread use of thiopurines and anti-tumor necrosis factors (TNFs) in inflammatory bowel disease (IBD) is a rising concern regarding their potential cancer risk. MEDLINE, EMBASE, and the Cochrane Library database were searched for articles regarding immunomodulators anti-TNF agents in IBD, hematologic malignancies, and solid tumors. Current evidences support that thiopurines and anti-TNFs used alone or in combination do not increase the overall cancer risk in IBD. Thiopurines use, with or without anti-TNFs, is associated with an increased risk of lymphoma, particularly non-Hodgkin lymphoma, in Crohn's disease. Combined treatment significantly increases the risk of a rare hepatosplenic T-cell lymphoma, particularly in young male patients with Crohn's disease. An increased risk of nonmelanotic skin cancer is also observed when using thiopurines in IBD, whereas a slightly increased risk of melanoma is observed when using anti-TNFs. The role played by immunomodulators in the development of other cancer types (i.e., urinary) as also by the severity of IBD is under investigation. Although the incidence of specific malignancies (lymphoma, skin cancers) seems to be increased by immunomodulators, their absolute number is low. As thiopurines and anti-TNFs are highly effective in IBD, current evidences support that in appropriate hands, their benefits overwhelm the cancer risk. However, a careful selection of both patients and timing of treatment is mandatory, particularly in young male patients with Crohn's disease. Immunomodulators should therefore be handled by experienced and dedicated gastroenterologists who aware of the potential, although low, cancer risk associated with their use in patients with IBD.Keywords
This publication has 81 references indexed in Scilit:
- Colorectal cancer in inflammatory bowel diseases: A population-based study (1976–2008)Inflammatory Bowel Diseases, 2012
- Incidence and Mortality of Colorectal Adenocarcinoma in Persons With Inflammatory Bowel Disease From 1998 to 2010Gastroenterology, 2012
- Decreasing Risk of Colorectal Cancer in Patients With Inflammatory Bowel Disease Over 30 YearsGastroenterology, 2012
- Risk of Colorectal Cancer in Patients With Ulcerative Colitis: A Meta-analysis of Population-Based Cohort StudiesClinical Gastroenterology and Hepatology, 2012
- Intestinal Inflammation and CancerGastroenterology, 2011
- Long-term complications, extraintestinal manifestations, and mortality in adult Crohnʼs disease in population-based cohortsInflammatory Bowel Diseases, 2011
- The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Definitions and diagnosisJournal of Crohn's and Colitis, 2010
- Effect of 5-Aminosalicylate Use on Colorectal Cancer and Dysplasia Risk: A Systematic Review and Metaanalysis of Observational StudiesAmerican Journal of Gastroenterology, 2005
- Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitisGastroenterology, 2004
- Intestinal and extra‐intestinal cancer in Crohn's disease: follow‐up of a population‐based cohort in Copenhagen County, DenmarkAlimentary Pharmacology & Therapeutics, 2004